Founding investor GE Ventures participated in a $33.5m series B round that boosted the gene therapy platform's total funding to more than $47m.
US-based gene therapy access platform Vineti secured $33.5m on Monday in a series B round featuring GE Ventures, the corporate venturing subsidiary of industrial product manufacturer General Electric (GE).
Venture capital firms Canaan Partners and DFJ co-led the round, which included VC fund Section 32, investment firm Casdin Capital, VC firm LifeForce Capital and unnamed additional investors.
Vineti has created cloud-based software that facilitates gene therapy development by integrating logistics, manufacturing and clinical data for personalised therapeutics and adding automation…
